XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
candidate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development   $ 4,048 $ 3,500 $ 7,669 $ 7,492  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of antibody drug conjugates obtained right and obligations | candidate           3
Aggregate upfront payments due upon execution in collaborative arrangement           $ 4,000
Refundable upfront payments in collaborative arrangement           1,000
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement           5,500
Research and development   $ 193 $ 65 $ 321 $ 133 $ 5,500
Sales based royalty percentage 5.00%         5.00%
Upfront cash payment $ 170          
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Ifinatamab Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Refundable upfront payments in collaborative arrangement           $ 500
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Refundable upfront payments in collaborative arrangement           500
Aggregate upfront payments due upon lapse of time in collaborative arrangement           750
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Raludotatug Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate upfront payments due upon lapse of time in collaborative arrangement           $ 750
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage           75.00%
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement           $ 2,000
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan and Ralduotatug Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate upfront payments due upon lapse of time in collaborative arrangement           $ 1,500